Post-treatment imaging with PET scans has shown promise in predicting which patients with stage II and III inoperable non-small cell lung cancer have aggressive tumors and need additional treatment, according to the preliminary study results reported at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Miami.

Cetuximab combined with chemoradiotherapy increases lung cancer survival while inducing side effects comparable to chemotherapy alone, offering promising phase II results that clinicians hope will roll over to an ongoing phase III trial.